ArticleEuropean journal of nuclear medicine and molecular imaging2017
Elevated tumor-to-liver uptake ratio (TLR) from
Article in European journal of nuclear medicine and molecular imaging, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 43 citations in OpenAlex.
- CAIX-targeted PET/CT in the evaluation of clear cell renal cell carcinoma: a head-to-head comparison with [European journal of nuclear medicine and molecular imaging · 2026Trial
- PET/CT-based quantification of intratumoral heterogeneity for predicting pathological complete response in breast cancer patients treated with neoadjuvant chemotherapy: A multicentre study.European journal of nuclear medicine and molecular imaging · 2026Article
- Texture analysis of [European journal of nuclear medicine and molecular imaging · 2026Observational
- Development and validation of anAnnals of nuclear medicine · 2025Article
- Visual and QuantitativeMolecular imaging and biology · 2025Article
- Fentanyl overdose: Temporal effects and prognostic factors in SKH1 mice.Basic & clinical pharmacology & toxicology · 2024Article
- Predictive value of metabolic parameters derived from preoperativeQuantitative imaging in medicine and surgery · 2023Article
- Prognostic value of TLR from FDG PET/CT in patients with margin-negative stage IB and IIA non-small cell lung cancer.European radiology · 2023Article
- Low TLR and PSMA-TV predict biochemical response to abiraterone acetate in metastatic prostate cancer patients developing castration resistance after chemohormonal therapy at hormone-sensitive stage.Journal of cancer research and clinical oncology · 2023Article
- Predictive value ofEuropean journal of nuclear medicine and molecular imaging · 2023Article
- PET/CT for Predicting Occult Lymph Node Metastasis in Gastric Cancer.Current oncology (Toronto, Ont.) · 2022Review
- Influence of Semiquantitative [Pharmaceuticals (Basel, Switzerland) · 2022Article
- Article
- The utility of 2-[European radiology · 2021Article
- 2-[European journal of nuclear medicine and molecular imaging · 2021Article
- Radiomics Features ofCancers · 2021Article
- Glucose Metabolism Reprogramming of Primary Tumor and the Liver Is Associated With Disease-Free Survival in Patients With Early NSCLC.Frontiers in oncology · 2021Article
- The Impact of Primary Tumor and Locoregional Metastatic Lymph Node SUVMolecular imaging and radionuclide therapy · 2020Article
- Evaluating Positron Emission Tomography-Based Functional Imaging Changes in the Heart After Chemo-Radiation for Patients With Lung Cancer.International journal of radiation oncology, biology, physics · 2020Article
- The PET-Derived Tumor-to-Liver Standard Uptake Ratio (SUVFrontiers in oncology · 2020Article
Corrections and comments
- Commented on by
Authors and funding
11 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeThe prognostic value of the tumor-to-liver uptake ratio (TLR) from 18-fluoro-2-deoxyglucose positron emission tomography/computed tomography (
methodsFrom April 2010 to December 2013, 504 consecutive CRC patients with different TNM stages (I-IV) underwent
resultsROC curve analysis demonstrated that TLR was superior to primary tumor SUVmax in predicting the risk of recurrence in stage IIA CRC. The optimal TLR cutoff was 6.2. Univariate analysis indicated that elevated TLR, tumor size, and lymphovascular/neural invasion correlated with DFS (P = 0.001, P = 0.002, and P = 0.001, respectively) and OS (P = 0.001, P = 0.003, and P < 0.001, respectively). The 1-, 3-, and 5-year DFS rates were 98.4%, 96.9%, and 96.9% for stage IIA CRC patients with lower TLR (≤6.2) versus 77.8%, 60.6%, and 60.6% for those with elevated TLR (>6.2), respectively. The 1-, 3-, and 5-year OS rates were 100.0%, 100.0%, and 98.3% for the patients with lower TLR versus 98.1%, 83.3%, and 74.3% for those with elevated TLR. Cox regression analysis showed that elevated TLR [>6.2; hazard ratio (HR): 3.109-57.463; P < 0.001] and tumor size (>4.4 cm; HR: 1.636-19.155; P = 0.006) were independent risk factors for DFS. Meanwhile, elevated TLR (>6.2; HR: 1.398-84.945; P = 0.023) and lymphovascular/neural invasion (positive; HR: 1.278-12.777; P = 0.017) were independent risk factors for OS.
conclusionElevated TLR predicted worse DFS and OS for stage IIA CRC patients and might serve as a potential radiological index to identify candidates for neoadjuvant or adjuvant chemotherapy. Stage IIA CRC patients with elevated TLR should be monitored carefully for early detection of possible recurrence.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.